D. E. Shaw & Co., Inc. Exelixis, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $2,423 - $3,093	-100 Reduced 0.12%	80,000 $2.43 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $1.87 Million - $2.34 Million	80,100	80,100 $1.94 Million

460

240M

2.04M

1.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.44B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.